Experimental Human Infection with Norwalk Virus Elicits a Surrogate Neutralizing Antibody Response with Cross-Genogroup Activity

Chimeric GII.4 Norovirus Virus-Like-Particle-Based Vaccines Induce Broadly Blocking Immune Responses

(2014) K. Debbink et al.   JOURNAL OF VIROLOGY

Analysis of early strains of the norovirus pandemic variant GII.4 Sydney 2012 identifies mutations in adaptive sites of the capsid protein

(2014) G.M. Giammanco et al.   VIROLOGY

Proposal for a unified norovirus nomenclature and genotyping

(2013) Annelies Kroneman et al.   ARCHIVES OF VIROLOGY

Epidemiology of human noroviruses and updates on vaccine development

(2013) Sasirekha Ramani et al.   CURRENT OPINION IN GASTROENTEROLOGY

Genotypic and Epidemiologic Trends of Norovirus Outbreaks in the United States, 2009 to 2013

(2013) E. Vega et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Determination of the 50% Human Infectious Dose for Norwalk Virus

(2013) Robert L. Atmar et al.   JOURNAL OF INFECTIOUS DISEASES

Isolation of cross-reactive human monoclonal antibodies that prevent binding of human noroviruses to histo-blood group antigens

(2013) Kyoko Higo-Moriguchi et al.   JOURNAL OF MEDICAL VIROLOGY

Characterization of Blockade Antibody Responses in GII.2.1976 Snow Mountain Virus-Infected Subjects

(2013) J. Swanstrom et al.   JOURNAL OF VIROLOGY

Pre-existing Immunity to Norovirus GII-4 Virus-Like Particles Does Not Impair de Novo Immune Responses to Norovirus GII-12 Genotype

(2013) Kirsi Tamminen et al.   VIRAL IMMUNOLOGY

The emergence and evolution of the novel epidemic norovirus GII.4 variant Sydney 2012

(2013) John-Sebastian Eden et al.   VIROLOGY

Noroviruses: The Perfect Human Pathogens?

(2012) A. J. Hall   JOURNAL OF INFECTIOUS DISEASES

The potential economic value of a human norovirus vaccine for the United States

(2012) Sarah M. Bartsch et al.   VACCINE

Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations

(2012) Gabriel I. Parra et al.   VACCINE

Immunogenetic Mechanisms Driving Norovirus GII.4 Antigenic Variation

(2012) Lisa C. Lindesmith et al.   PLoS Pathogens

Serum Hemagglutination Inhibition Activity Correlates with Protection from Gastroenteritis in Persons Infected with Norwalk Virus

(2011) Rita Czakó et al.   Clinical and Vaccine Immunology

Norovirus Vaccine against Experimental Human Norwalk Virus Illness

(2011) Robert L. Atmar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Serological Correlate of Protection against Norovirus‐Induced Gastroenteritis

(2010) Amanda Reeck et al.   JOURNAL OF INFECTIOUS DISEASES

Phylodynamic Reconstruction Reveals Norovirus GII.4 Epidemic Expansions and their Molecular Determinants

(2010) J. Joukje Siebenga et al.   PLoS Pathogens

Herd Immunity to GII.4 Noroviruses Is Supported by Outbreak Patient Sera

(2009) J. L. Cannon et al.   JOURNAL OF VIROLOGY

Heterotypic Humoral and Cellular Immune Responses following Norwalk Virus Infection

(2009) L. C. Lindesmith et al.   JOURNAL OF VIROLOGY

Alphavirus-Adjuvanted Norovirus-Like Particle Vaccines: Heterologous, Humoral, and Mucosal Immune Responses Protect against Murine Norovirus Challenge

(2009) A. D. LoBue et al.   JOURNAL OF VIROLOGY

Atomic resolution structural characterization of recognition of histo-blood group antigens by Norwalk virus

(2008) J.-M. Choi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mechanisms of GII.4 Norovirus Persistence in Human Populations

(2008) Lisa C Lindesmith et al.   PLOS MEDICINE